T-62 ((2-amino-4,5,6,7-tetrahydro-1-benzothien-3-yl)(4-chlorophenyl)methanone) is a small-molecule allosteric potentiator of agonist function at the adenosine A1 receptor, developed by Edward Leung for the treatment of various pain states in a mammal and human subjects.

Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier. Pfizer conducted multicenter, randomized, double-bind, placebo-controlled trials to evaluate the safety and efficacy of prinomastat in combination with standard chemotherapy in patients with advanced hormone refractory prostate cancer and non-small cell lung cancer. However, this study has been terminated for the reason that Prinomastat did not improve the outcome of chemotherapy in non-small cell Lung cancer patients.

Mesudipine, a dihydropyridine analog, is a calcium antagonistic drug (slow channel blocker). It blocks electrical activity in smooth muscle cells and Purkinje fibers.

Metanixin is an analgesic and anti-inflammatory agent.

Lintopride is a benzamide, eliciting prokinetic properties on the upper gut in several animal models. Lintopride increases gastric emptying, stimulates antral and duodenal motility and accelerates intestinal transit in animals. In canines it also increases lower oesophageal sphincter (LOS) pressure and reinforces peristaltic waves after wet swallowing, indicating a stimulatory action which could potentially be greater than that of metoclopramide. The 5HT-4 agonist lintopride increases LOS basal pressure and the amplitude of peristaltic waves of the oesophagus following a single intravenous dose in healthy subjects. The action of lintopride on LOS basal pressure and oesophageal peristaltic waves could be beneficial in patients with gastro-oesophageal reflux disease.

Thiacetarsamide is a drug containing trivalent arsenic. In the USA it was used for the treatment of Heartworm Infection in dogs and cats under tradename Caparsolate, however, it was discontinued because of the availability of safer alternatives. The mechanism of action for thiacetarsamide is modulation of glucose uptake and metabolism; inhibition of glutathione reductase, and alteration of the structure and function of the surface of the intestinal epithelium of the parasites.

Lomeguatrib is a O6-methylguanine-DNA-methyl-transferase inhibitor which was developed by AstraZeneca for the treatment of cancer. It was tested in phase I and II of clinical trials for the treatment of colorectal cancer, melanoma and other solid tumors.

Tifemoxone is a tetrahydrooxazine derivative patented by Delalande S.A. as an analgesic, spasmolytic, antidepressive agent. In preclinical studies, Tifemoxone caused thyreotoxicity, hairlessness and increased in water consumption and diuresis and in addition it had a strong hepatotoxic effect especially in the dog.

Timirdine (also known as EGY-4201) is an iminothiazolidine derivative patented by EGIS Gyogyszergyar as an antidepressant. In the behavioral despair model and in antagonizing the effect of tetrabenazine, Timirdine efficacy was considerably higher than that of several tricyclic and second-generation antidepressant drugs. Timirdine was also active in inhibiting the hypothermic effect of apomorphine. It potentiated the lethal effect of yohimbine, the hypermotility provoked by L-dopa, and the stereotypy induced by D-amphetamine. In contrast to amitriptyline and nomifensine, Timirdine showed neither sedative nor stimulant actions on spontaneous and conditioned behavior.